Compare Globus Medical Inc. Class A Common Stock (GMED) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs HCA Health Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while HCA Health Inc trades at $474.89 (market cap $101.85B). The key difference: HCA Health Inc is far larger — about 9.9× Globus Medical Inc. Class A Common Stock's market cap, and HCA Health Inc pays a 0.66% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and HCA Health Inc for 76 Days on average.
| GMED | HCA | |
|---|---|---|
Market Cap | $10.25B | $101.85B |
Volume | 1,059,528 | 1,081,388 |
Sector | Health | Health |
52-Week High | $96.82 | $545.13 |
52-Week Low | $58.33 | $361.32 |
Typical Hold Time | 0 Days | 76 Days |
Enterprise Value | $9.76B | $152.39B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HCA Healthcare trades at $460.75, up 0.47% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $7.59 exceeding expectations. Revenue grew to $75.60 billion in 2025, and net income reached $6.78 billion. Analyst consensus is bullish, with a $461.12 price target. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations.
Outlook remains positive due to solid demand and cost controls, but risks include regulatory scrutiny and debt levels. The stock offers growth potential from operational efficiency, though investors should monitor legal developments and payer-mix pressures. Valuation metrics like a P/E of 15.45 suggest reasonable pricing relative to earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
